OBJECT: Nitric oxide has been associated with epileptogenesis. Previous studies have shown increased expression of N-methyl-d-aspartate (NMDA) subunit NR2B receptors in epileptic dysplastic human neocortex. The expression of neuronal nitric oxide synthase (nNOS), and its relation to this subunit NR2B in epileptic dysplastic tissue has never been addressed. METHODS: Ten patients with medically intractable epilepsy caused by focal cortical dysplasia (CD), and 2 patients with mesial temporal sclerosis (control group) underwent pre- and/or intraoperative invasive monitoring evaluations. Cortical samples from epileptogenic and nonepileptogenic areas were collected from each patient intraoperatively. Samples were processed for cresyl violet staining, immunocytochemical tests with nNOS, NeuN, and NR2B, and immunofluorescence analyses to evaluate colocalized immunoreactivity between nNOS and NR2B. RESULTS: All samples obtained in the patients with epilepsy revealed CD in various degrees. In the nonepileptic sample group, cresyl violet staining revealed normal cortical architecture in 9 samples, but a mild degree of CD in 3. The density and intensity of nNOS-stained neurons was remarkably increased in the epileptic tissue compared with nonepileptic samples (p < 0.05). Two types of nNOS-stained neurons were identified: Type I, expressing strong nNOS immunoreactivity in larger neurons; and Type II, expressing weak nNOS immunoreactivity in slightly smaller neurons. Different from Type I neurons, Type II nNOS-stained neurons revealed immunoreactivity colocalized with NR2B antibody. CONCLUSIONS: The overexpression of nNOS in the epileptic samples and the immunoreactivity colocalization between nNOS and NR2B may suggest a possible role of nNOS and NO in the pathophysiological mechanisms related to in situ epileptogenicity.
OBJECT: Nitric oxide has been associated with epileptogenesis. Previous studies have shown increased expression of N-methyl-d-aspartate (NMDA) subunit NR2B receptors in epileptic dysplastic human neocortex. The expression of neuronal nitric oxide synthase (nNOS), and its relation to this subunit NR2B in epileptic dysplastic tissue has never been addressed. METHODS: Ten patients with medically intractable epilepsy caused by focal cortical dysplasia (CD), and 2 patients with mesial temporal sclerosis (control group) underwent pre- and/or intraoperative invasive monitoring evaluations. Cortical samples from epileptogenic and nonepileptogenic areas were collected from each patient intraoperatively. Samples were processed for cresyl violet staining, immunocytochemical tests with nNOS, NeuN, and NR2B, and immunofluorescence analyses to evaluate colocalized immunoreactivity between nNOS and NR2B. RESULTS: All samples obtained in the patients with epilepsy revealed CD in various degrees. In the nonepileptic sample group, cresyl violet staining revealed normal cortical architecture in 9 samples, but a mild degree of CD in 3. The density and intensity of nNOS-stained neurons was remarkably increased in the epileptic tissue compared with nonepileptic samples (p < 0.05). Two types of nNOS-stained neurons were identified: Type I, expressing strong nNOS immunoreactivity in larger neurons; and Type II, expressing weak nNOS immunoreactivity in slightly smaller neurons. Different from Type I neurons, Type II nNOS-stained neurons revealed immunoreactivity colocalized with NR2B antibody. CONCLUSIONS: The overexpression of nNOS in the epileptic samples and the immunoreactivity colocalization between nNOS and NR2B may suggest a possible role of nNOS and NO in the pathophysiological mechanisms related to in situ epileptogenicity.
Authors: Irina V Chadaeva; Mikhail P Ponomarenko; Dmitry A Rasskazov; Ekaterina B Sharypova; Elena V Kashina; Marina Yu Matveeva; Tatjana V Arshinova; Petr M Ponomarenko; Olga V Arkova; Natalia P Bondar; Ludmila K Savinkova; Nikolay A Kolchanov Journal: BMC Genomics Date: 2016-12-28 Impact factor: 3.969
Authors: Mikhail Ponomarenko; Dmitry Rasskazov; Olga Arkova; Petr Ponomarenko; Valentin Suslov; Ludmila Savinkova; Nikolay Kolchanov Journal: Biomed Res Int Date: 2015-10-04 Impact factor: 3.411
Authors: Olga V Arkova; Mikhail P Ponomarenko; Dmitry A Rasskazov; Irina A Drachkova; Tatjana V Arshinova; Petr M Ponomarenko; Ludmila K Savinkova; Nikolay A Kolchanov Journal: BMC Genomics Date: 2015-12-16 Impact factor: 3.969
Authors: Petr Ponomarenko; Dmitry Rasskazov; Valentin Suslov; Ekaterina Sharypova; Ludmila Savinkova; Olga Podkolodnaya; Nikolay L Podkolodny; Natalya N Tverdokhleb; Irina Chadaeva; Mikhail Ponomarenko; Nikolay Kolchanov Journal: Biomed Res Int Date: 2016-08-22 Impact factor: 3.411
Authors: Irina V Chadaeva; Petr M Ponomarenko; Dmitry A Rasskazov; Ekaterina B Sharypova; Elena V Kashina; Dmitry A Zhechev; Irina A Drachkova; Olga V Arkova; Ludmila K Savinkova; Mikhail P Ponomarenko; Nikolay A Kolchanov; Ludmila V Osadchuk; Alexandr V Osadchuk Journal: BMC Genomics Date: 2018-02-09 Impact factor: 3.969
Authors: Xue-Mei Zhang; Yan Cai; Yaping Chu; Er-Yun Chen; Jia-Chun Feng; Xue-Gang Luo; Kun Xiong; Robert G Struble; Richard W Clough; Peter R Patrylo; Jeffrey H Kordower; Xiao-Xin Yan Journal: Front Neuroanat Date: 2009-10-13 Impact factor: 3.856
Authors: Mikhail P Ponomarenko; Olga Arkova; Dmitry Rasskazov; Petr Ponomarenko; Ludmila Savinkova; Nikolay Kolchanov Journal: Front Immunol Date: 2016-04-04 Impact factor: 7.561